Furthermore, the fact that we do not see significant probe accumulation in patients with unclassified lung fibrosis provides some support for the potential to use cathepsin probes to stratify patients with IPF such that they can be followed and eventually treated with new therapies that are currently in clinical trials. This evidence concerns the gene CTSS and idiopathic interstitial pneumonia.